Oncology Central

Pembrolizumab becomes the first and only immunotherapy to be recommended by NICE for urothelial carcinoma patients

NICE has issued final guidance recommending the use of the immunotherapy KEYTRUDA® (pembrolizumab) within the cancer drugs fund (CDF) as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
To view restricted content, please:


Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.